FDAsafety guidance72% confidence
January - March 2026 | New Safety Information or Potential Signals of Serious Risks Identified by the FDA Adverse Event Monitoring System (AEMS)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Boehringer Ingelheim.
Regulatory Analysis
January - March 2026 | New Safety Information or Potential Signals of Serious Risks Identified by the FDA Adverse Event Monitoring System (AEMS)
Supporting Context
- Therapeutic area
- Pulmonology · Fibrosing Interstitial Lung Disease
- Sub-indication
- Ild
Related signal: Boehringer Ingelheim's Nerandomilast Trial for Fibrosing ILD Shows Potential for Disease Progression